A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Status:
Recruiting

Trial end date:
2022-07-31

Target enrollment:

Participant gender:

The purpose of this study is to evaluate the effects of KER-050 on anemia in patients with very low, low or intermediate risk MDS.

Phase 2

Keros Therapeutics